Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T98917
|
|||||
Target Name |
Mitochondrial rRNA methyltransferase 2 (MRM2)
|
|||||
Synonyms |
rRNA methyltransferase 2, mitochondrial; Protein ftsJ homolog 2; 16S rRNA [Um1369] 2'-O-methyltransferase; 16S rRNA (uridine(1369)-2'-O)-methyltransferase
Click to Show/Hide
|
|||||
Gene Name |
MRM2
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 3 Target-related Diseases | + | ||||
1 | Bronchitis [ICD-11: CA20] | |||||
2 | Prostate disease [ICD-11: GA91] | |||||
3 | Urinary tract infection [ICD-11: GC08] | |||||
Function |
S-adenosyl-L-methionine-dependent 2'-O-ribose methyltransferase that catalyzes the formation of 2'-O-methyluridine at position 1369 (Um1369) in the 16S mitochondrial large subunit ribosomal RNA (mtLSU rRNA), a universally conserved modification in the peptidyl transferase domain of the mtLSU rRNA.
Click to Show/Hide
|
|||||
BioChemical Class |
Methyltransferase
|
|||||
UniProt ID | ||||||
EC Number |
EC 2.1.1.-
|
|||||
Sequence |
MAGYLKLVCVSFQRQGFHTVGSRCKNRTGAEHLWLTRHLRDPFVKAAKVESYRCRSAFKL
LEVNERHQILRPGLRVLDCGAAPGAWSQVAVQKVNAAGTDPSSPVGFVLGVDLLHIFPLE GATFLCPADVTDPRTSQRILEVLPGRRADVILSDMAPNATGFRDLDHDRLISLCLTLLSV TPDILQPGGTFLCKTWAGSQSRRLQRRLTEEFQNVRIIKPEASRKESSEVYFLATQYHGR KGTVKQ Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | PDB |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
1 | Plazomicin | Drug Info | Approved | Urinary tract infection | [1] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | Plazomicin | Drug Info | [1] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: Ademetionine | Ligand Info | |||||
Structure Description | Crystal Structure of Human FtsJ homolog 2 (E.coli) protein in complex with S-adenosylmethionine | PDB:2NYU | ||||
Method | X-ray diffraction | Resolution | 1.76 Å | Mutation | Yes | [2] |
PDB Sequence |
SYRSRSAFKL
10 LEVNERHQIL20 RPGLRVLDCG30 AAPGAWSQVA40 VQKVNAAGTD50 PSSPVGFVLG 60 VDLLHIFPLE70 GATFLCPADV80 TDPRTSQRIL90 EVLPGRRADV100 ILSDMAPNAT 110 GFRDLDHDRL120 ISLCLTLLSV130 TPDILQPGGT140 FLCKTWAGSQ150 SRRLQRRLTE 160 EFQNVRIIKP170 EVYFLATQYH188 G
|
|||||
|
SER4
4.265
SER6
3.468
ALA7
4.765
ASP28
4.851
GLY30
2.900
ALA31
3.510
ALA32
3.067
PRO33
3.067
GLY34
2.997
ALA35
2.915
TRP36
2.866
VAL61
4.397
ASP62
2.660
|
|||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Similarity Proteins
Human Tissue Distribution
|
There is no similarity protein (E value < 0.005) for this target
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | In vitro activity of plazomicin against -lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).J Antimicrob Chemother. 2017 Oct 1;72(10):2792-2795. | |||||
REF 2 | The Crystal Structure of Human FtsJ homolog 2 (E.coli) protein in complex with AdoMet |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.